In our study, we found that, as a clinical treatment of DM, sitagliptin also plays a role of ROS scavenger, which can inhibit the activation of NFκB pathway and effectively alleviate chronic liver injury and hepatotoxicity induced by STZ as evidenced by decreased serum ALT, AST, and LDH levels. This evidence concerns the gene NFKB1 and diabetes mellitus.